What is Dexcom?

What is Dexcom?

Dexcom is a public continuous glucose monitoring company headquartered in San Diego, CA. It reported $4.662B of 2025 revenue and operates at global enterprise scale.

Dexcom operates in continuous glucose monitoring with a portfolio spanning Continuous glucose monitoring sensors, transmitters, receivers, apps, and data services. The company reported $4.662B of 2025 revenue, employs about 10,000+, and trades as Nasdaq: DXCM. Its customer base is large, regulated, and relationship-driven, with purchasing decisions shaped by clinical outcomes, compliance, reimbursement, operating leverage, and long-term supply reliability.

The company's scale comes from durable demand in healthcare, recurring consumables or services, installed bases, payer or provider relationships, and disciplined capital allocation. Unlike early-stage software companies, Dexcom is evaluated through revenue growth, margins, cash flow, reimbursement exposure, procedure or prescription volume, quality, and regulatory execution.

For sellers, Dexcom is not a single buying center. The practical map includes procurement, finance, clinical, IT, security, compliance, operations, supply chain, commercial teams, and business-unit executives. Strong pitches connect directly to patient outcomes, cost-to-serve, risk reduction, revenue capture, uptime, or measurable productivity.

Sources:Dexcom resultsDexcom annual reports

What does Dexcom offer?

Dexcom offers healthcare products and services across Continuous glucose monitoring sensors, transmitters, receivers, apps, and data services.

Sources:Dexcom websiteDexcom annual reports

How does Dexcom make money?

Dexcom earns revenue from recurring CGM sensors and related hardware, plus software-enabled data and ecosystem integrations across diabetes and metabolic health.

Dexcom earns revenue from recurring CGM sensors and related hardware, plus software-enabled data and ecosystem integrations across diabetes and metabolic health. In 2025, that model produced $4.662B of revenue, showing the scale of the installed base, service footprint, payer/provider contracts, or distribution volume behind the business.

Pricing is reimbursement-, channel-, cash-pay-, prescription-, sensor-duration-, payer-contract-, and geography-driven; recurring sensor replacement is the core economic engine. That makes the relevant "pricing tier" for sellers an enterprise contracting motion: account segmentation, compliance review, value analysis, legal terms, security review, reimbursement impact, and multi-year renewal economics.

Growth is driven by a mix of market expansion, procedure or prescription volume, product launches, acquisitions, geographic reach, contract renewals, operational efficiency, and technology adoption. Vendors should expect rigorous procurement, documented ROI, data-security requirements, and evidence that the product can work inside regulated healthcare operations.

Sources:Dexcom resultsDexcom annual reports

Who leads Dexcom?

Dexcom is led by Jake Leach, with finance, operations, clinical, technology, and business-unit leaders shaping major enterprise decisions.

Sources:Dexcom leadershipDexcom annual reports

How do you contact Dexcom's leadership?

Dexcom publishes investor-relations, media, supplier, customer, and compliance channels, but it does not publish verified personal executive emails for the listed leaders. Use the public investor-relations route (investorrelations@dexcom.com) or official contact forms rather than guessed personal addresses.

• Jake LeachChief Executive Officerinvestorrelations@dexcom.com
• Kevin SayerExecutive Chairmaninvestorrelations@dexcom.com
• Jereme SylvainExecutive Vice President and Chief Financial Officerinvestorrelations@dexcom.com

Sources:Dexcom contactDexcom leadership

How much funding has Dexcom raised?

Dexcom is a mature public company, not a venture-backed startup. It trades as Nasdaq: DXCM, had an approximate ~$30B market capitalization in June 2026, and funds growth through operating cash flow, debt markets, public equity access, and acquisition capacity.

Dexcom's capital history is a public-company story rather than a disclosed venture-round history. The relevant milestones are founding in 1999, public-market access, acquisitions, debt capacity, dividends or buybacks where applicable, and reinvestment in regulated healthcare capabilities.

The company reported $4.662B of 2025 revenue and operates with the financing tools expected of a large public healthcare company. Capital is directed toward product development, clinical evidence, facilities, inventory, technology, acquisitions, compliance, reimbursement capabilities, and shareholder returns depending on the business model.

Seller signal: Dexcom has meaningful buying power, but budget access is tied to risk, ROI, compliance, and executive sponsorship. Vendors should map proposals to cost reduction, growth, care quality, automation, supply resilience, cybersecurity, data quality, or measurable operating improvement.

Sources:Dexcom resultsNasdaq: DXCM market data

How did Dexcom get here?

Dexcom grew through founding, public-market scale, product expansion, acquisitions, and healthcare-market execution.

Sources:Dexcom annual reportsDexcom results

Who are Dexcom's competitors?

Dexcom competes with companies that overlap in customers, budgets, clinical categories, distribution channels, or healthcare services.

Sources:Dexcom annual reportsDexcom website